MedWatch

Regions slam the door on direct contact between doctors and companies

In the future, it is up to each hospital management to decide which doctors and nurses will receive supplementary training sponsored by the pharmaceutical industry. The new guidelines win praise among doctors as well as the industry.

Photo: /ritzau/Peter Vintergaard

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Analytikere: Ozempic udfordres af nye doser fra rival

Opdateret kl. 15:14: Eli Lilly har kan med højdosisudgaver af sin ugentlige GLP-1-analog, Trulicity, vise sig at blive en seriøs konkurrent til Novo Nordisks Ozempic, vurderer analytikere. Novo selv er ikke bekymret.

Rival-produkt overgår Novos guldæg i klinisk praksis

Data fra den virkelige verden viser, at GLP-1-analogen Trulicity fra Eli Lilly er mere effektiv end både Novo Nordisks Victoza og et produkt fra Astrazeneca. Samtidig har et andet studie vist lovende takter for højere doser af Eli Lillys produkt.

Related articles